Overview

A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

Status:
Recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate the clinical efficacy of rozanolixizumab in maintenance treatment and assess safety and tolerability of rozanolixizumab in adult study participants with primary immune thrombocytopenia (ITP).

Phase:

Phase 3

Details

Lead Sponsor:

UCB Biopharma SRL

Treatments:

Rozanolixizumab